600674 Disclosed herein is a quinoline-2-carboxamide compounds of formula (I), wherein the variables are defined in the specification, and the use thereof in the treatmet of a disease mediated by the muscarinic M1 receptor, wherein said disease is selected from the group consisting of Alzheimer's disease, schizophrenia, pain or sleep disorders. Specific embodiments of the quinoline-2-carboxamide compound include: 4-[(6-chloropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]quinoline-2-carboxamide, N-[(3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl]-4-{ [6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]methyl} quinoline-2-carboxamide, 4-[fluoro(6-methoxypyridin-3-yl)methyl]-N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]quinoline-2-carboxamide hydrate, 4-[(2-ethoxypyridin-4-yl)methyl]-N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]quinoline-2-carboxamide.
